|Articles|June 20, 2011

Risk-Based Approaches to Clinical Investigations

The Risk-Based Approaches to Clinical Investigations compendia consists of conference presentation materials submitted by speakers and industry thought leaders

RELATED
- Snapshot Shows Targeted Site Monitoring Trend
- Risk-Based Approach to Monitoring
- Has FDA Guidance on Risk-based Monitoring Impacted SDV Coverage Yet?More in Risk-Based Monitoring

This Compendium consists of presentation materials submitted by speakers that complement their presentations from CBI’s Risk-Based Approaches to Clinical Investigations. CBI has provided information and networking opportunities for thousands of executives in industries such as pharmaceuticals, biotech, medical devices and managed care. We understand what an important resource this material is and we have made a concerted effort to secure biographical sketches, outlines and related materials from the conference.

View agenda from this past conference

PRESENTATIONS:

- Dean Gittleman MS, Senior Director, Operations, Target Health Inc.Read Bio

- Imogene Grimes Ph.D., Senior Director, Biostatistics, Otsuka Pharmaceutical Development & Commercialization, Inc. Read Bio

- Darlene Kalinowski, Associate Director, eDC Operations, Bristol-Myers SquibbRead Bio

- Jules T. Mitchel MBA, Ph.D., President, Target Health Inc.Read Bio

- Anne Marie Murphy, Principal, Hyman, Phelps & McNamaraRead Bio

- Mary Oster, Board Chair, New England Institutional Review BoardRead Bio

- Sharon S. Reinhard M.S., Associate Director, Compliance Operations & Oversight, Endo PharmaceuticalsRead Bio

- Vadim Tantsyura MS, MA, DrPh (c) Clinical Trial Operations Manager, Sanofi
- Vadim Tantsyura OpeningRead Bio

- Kerri Weingard NP, Research Director, Accumed Research AssociatesRead Bio

- Christian Yavorsky Ph.D. Chief Science Officer & Clinical Director, CROnos Clinical Consulting ServicesRead Bio

- Stephen Young, Senior Product Director, Medidata SolutionsRead Bio

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

© JHVEPhoto - © JHVEPhoto - stock.adobe.com

September 16th, 2026

FDA Opens Applications for Expedited IND Pilot Designed to Accelerate First-in-Human Trial Timelines

The pilot pairs drug sponsors with qualified research institutions to compress the path from drug identification to first-in-human study through rolling submission review and earlier coordination of institutional review board and site activation activities.

© FlowStudio - © FlowStudio - stock.adobe.com

September 16th, 2026

Benchmarking Study Finds Clinical Trial Performance Is Shaped by Operating Model Design, Not Sourcing Strategy

A Syneos Health-announced study from Tufts Center for the Study of Drug Development finds no single sourcing model consistently outperforms others, pointing instead to vendor coordination, governance, and fit-for-purpose design as the real performance drivers.

This article summarizes the FDA's four-part Patient-Focused Drug Development (PFDD) guidance series, the parallel mechanisms emerging in the European Union and the United Kingdom, the operational gaps sponsors most often encounter, and the areas in which large-scale, structured, patient-reported real-world data can and cannot contribute to a PFDD-aligned research plan. Credit: Stock.Adobe.com/Bordinthorn.

September 16th, 2026

Operationalizing the Patient Voice: Converging U.S., EU, and UK Requirements and the Role of Real-World Patient-Reported Data

Regulatory expectations for patient input in drug development have shifted from aspiration to documented methodology across three major jurisdictions.

September 16th, 2026

The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data

This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.

September 16th, 2026

How Clinical Teams Can Build Real Trust With Patient Advocacy Organizations

In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, outlines what it takes to move beyond transactional engagement and treat patient advocacy organizations as long-term partners in the science and the care.

September 16th, 2026

ACT Brief: Epilepsy Trial Feasibility and Family Realities, CRO Partnerships and Strategic Value, and Cortisol and GLP-1 Response

In today's ACT Brief, we examine what families with rare epilepsy teach about trial feasibility, how preclinical CRO partnerships are evolving beyond transactional services, and why cortisol dysregulation limits GLP-1 effectiveness in diabetes.

Preclinical CROs are evolving from transactional vendors into strategic partners, with trust, talent, AI, and shared accountability driving value in 2026. Credit: Stock.Adobe.com/Gorodenkoff

September 15th, 2026

The Evolution of Preclinical CRO Strategic Partnerships: From Transactional Services to Value-Driven Ecosystems in 2026

As the life sciences industry continues to evolve, the ability to effectively manage and leverage preclinical CRO partnerships is set to become a defining characteristic of successful biopharma companies.

September 15th, 2026

What the Epilepsy Community Has Taught Us About Trial Feasibility

In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.